Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review

Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

Abstract

No abstract available.

• Item Type: Articles (Letter)
• Additional Information: This work was in part funded by a Chief Scientist Office Lectureship (number PCL/20/10) to J.S.L.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Lang, Professor Ninian and Mark, Professor Patrick and Elyan, Dr Benjamin and Lees, Jennifer and Rankin, Dr Stephen and Jones, Professor Robert
• Authors: Elyan, B. M.P., Rankin, S., Jones, R., Lang, N. N., Mark, P. B., and Lees, J. S.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences; College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Kidney Medicine
• Publisher: Elsevier
• ISSN: 2590-0595
• ISSN (Online): 2590-0595
• Published Online: 16 May 2023
• Copyright Holders: Copyright © 2023 Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
• First Published: First published in Kidney Medicine 5(7):100672
• Publisher Policy: Reproduced under a Creative Commons License